The National Advertising Division found certain claims for Sanofi’s eczema treatment DUPIXENT supported but recommended the company modify or discontinue other claims following a challenge by Galderma. NAD determined that claims about staying ahead of eczema, blocking a key source of inflammation, healing skin from within, and 90% clearer skin were supported, while an animated mechanism-of-action video likely conveyed an unsupported message. The division recommended that Sanofi modify or discontinue television claims about long-lasting clearer skin and fast itch relief to clearly disclose how many patients achieved the results or that the results reflected treatment with DUPIXENT combined with topical corticosteroids. NAD also found that a prescriber-facing claim of itch reduction starting as early as day 2 was not supported by the post hoc analysis and should be discontinued or modified. Sanofi stated it will comply with NAD’s recommendations.
Sanofi SANAD recommends modifying or discontinuing certain DUPIXENT claims, which may affect marketing and sales.
